Discovery Hub
H-gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV1-8*01 (85.7%) -(IGHD) -IGHJ6*01 (85.7%) G119>D (109), CDR-IMGT [8.8.11] (26-33.51-58.97-107))(1-118) -Homo sapiens IGHG1*01 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfide with L-kappa light chain humanized (1'-220') [V-KAPPA (Homo sapiens IGKV4-1*01 (88.1%) -IGKJ2*01 (91.7%) I126>R (112), CDR-IMGT [12.3.9] (27'-38'.56'-58'.95'-103')) (1'-113') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (159'), V101 (197')) (114'-220')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, lacking the glutamine synthetase (GS-KO) gene and alpha-(1,6)-fucosyltransferase (FUT8-KO) gene, glycoform alfa

H-gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV1-801 (85.7%) -(IGHD) -IGHJ601 (85.7%) G119>D (109), CDR-IMGT [8.8.11] (26-33.51-58.97-107))(1-118) -Homo sapiens IGHG101 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfide with L-kappa light chain humanized (1'-220') [V-KAPPA (Homo sapiens IGKV4-101 (88.1%) -IGKJ201 (91.7%) I126>R (112), CDR-IMGT [12.3.9] (27'-38'.56'-58'.95'-103')) (1'-113') -Homo sapiens IGKC01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (159'), V101 (197')) (114'-220')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, lacking the glutamine synthetase (GS-KO) gene and alpha-(1,6)-fucosyltransferase (FUT8-KO) gene, glycoform alfa

Malignant Solid Tumor

Jiangsu Aosaikang Pharmaceutical Co., Ltd.monoclonal_antibodyPhase 1/2Active

45/ 100

Provisional rating · Methodology v0.2

Rating breakdown

44 Active assets in the Malignant Solid Tumor cohort.

Asset / Sponsor	Phase	Rating
Nivolumab Bristol-Myers Squibb	Phase 2	BB
CIS-DIAMMINEDICHLOROPLATINUM II Genmab	Phase 2	B
Irinotecan Tianjin Medical University Cancer Institute and Hospital	Phase 2	B
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER Eli Lilly and Company	Phase 2	B
(+)-VINCRISTINE Tianjin Medical University Cancer Institute and Hospital	Phase 2	B

View all 50 →

Order a full diligence report on this asset.

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.